sub:assertion {
d:DB00176 dv:ddi-interactor-in dr:DB00176_DB00540 .
d:DB00540 dv:ddi-interactor-in dr:DB00176_DB00540 .
dr:DB00176_DB00540 dct:identifier "drugbank_resource:DB00176_DB00540" ;
dct:title "DDI between Fluvoxamine and Nortriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Fluvoxamine and Nortriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB00540]"@en .
}